



OPEN

Development and validation of a visual field cluster in retinitis pigmentosa

Takashi Omoto¹, Akio Oishi^{2,3}, Ryo Asaoka^{1,4,5,8,9✉}, Yuri Fujino^{1,4,6}, Hiroshi Murata¹, Keiko Azuma¹, Manabu Miyata², Ryo Obata¹ & Tatsuya Inoue^{1,7}

The aim was to establish and evaluate a new clustering method for visual field (VF) test points to predict future VF in retinitis pigmentosa. A Humphrey Field Analyzer 10-2 test was clustered using total deviation values from 858 VFs. We stratified 68 test points into 24 sectors. Then, mean absolute error (MAE) of the sector-wise regression with them (S1) was evaluated using 196 eyes with 10 VF sequences and compared to pointwise linear regression (PLR), mean sensitivity of total area (MS) and also another sector-wise regression basing on VF mapping for glaucoma (29 sectors; S2). MAE with S1 were smaller than with PLR when between the first-third and first-seventh VFs were used. MAE with the method were significantly smaller than those of S2 when between the first-sixth and first-ninth VFs were used. The MAE of MS was smaller than those with S1 only when first to 3rd and first to 4th VFs were used; however, the prediction accuracy became far larger than any other methods when larger number of VFs were used. More accurate prediction was achieved using this new sector-wise regression than with PLR. In addition, the obtained cluster was more useful than that for glaucoma to predict progression.

Retinitis pigmentosa (RP) is a progressive hereditary retinal dystrophy in which degeneration of retinal photoreceptors causes nyctalopia and progressive visual field (VF) defects^{1–3}. To evaluate disease progression, VF tests, especially in the central area, such as the Humphrey Field Analyzer (HFA; Carl Zeiss Meditec AG, Dublin, CA, USA) 10-2 tests often are used^{3–5}. This measurement is important not only because it is essential to assess disease stage, but also the results are associated closely with vision-related quality of life as confirmed in RP⁶. In clinical settings, future VFs often are predicted using measured mean deviation (MD) values (MD trend analysis). However, MD reflects the values in the total area and, hence, focal VF change cannot be assessed. In contrast, pointwise linear regression (PLR) has the advantage that VF can be predicted at each test point. However, prediction often is not accurate particularly when short VF series are used^{7–9}, because measurement noise is considerable even with good reliability indices^{10,11} and also because short¹² and long-term VF sensitivity fluctuations occur¹³. Cluster-wise regression is a compromise between these two methods^{14–16}.

We previously reported that this approach is advantageous when predicting future VFs with the HFA 24-2 test compared to PLR in glaucoma cases^{17,18}. Indeed, cluster analysis is in clinical use, having been adopted in Octopus 900 EyeSuite software (Haag-Streit, Inc., Köniz, Switzerland)¹⁹. However, to our knowledge, no method exists to cluster VF (HFA 10-2 test) in RP. We established a new VF cluster for RP with the HFA 10-2 test, and investigated whether this approach was useful to improve prediction accuracy when predicting future VF.

Results

Demographic data for the training and testing datasets are shown in Tables 1 and 2, respectively. Mean age \pm standard deviation (SD) and mean MD values at the first VF were 51.3 ± 15.7 years and -17.9 ± 10.5 dB, respectively, for the training dataset, and 47.7 ± 12.1 years and -16.4 ± 8.0 dB, respectively, for the testing dataset. The observation period between the first and 10th VF was 8.1 ± 1.9 years.

¹Department of Ophthalmology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. ²Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. ³Department of Ophthalmology and Visual Sciences, Nagasaki University, Nagasaki, Japan. ⁴Department of Ophthalmology, Seirei Hamamatsu General Hospital, Shizuoka, Japan. ⁵Seirei Christopher University, Shizuoka, Japan. ⁶Department of Ophthalmology, Shimane University Faculty of Medicine, Izumo, Japan. ⁷Department of Ophthalmology and Micro-Technology, Yokohama City University, Kanagawa, Japan. ⁸Nanovision Research Division, Research Institute of Electronics, Shizuoka University, Shizuoka, Japan. ⁹The Graduate School for the Creation of New Photonics Industries, Shizuoka, Japan. ✉email: rásaoka-tyk@umin.ac.jp

Variables	Values
Eye, right:left	426:432
Age, mean \pm SD, y	51.3 \pm 15.7
MD, mean \pm SD, dB	-17.9 \pm 10.5

Table 1. Demographic data of the patients for the cluster developing. *SD* standard deviation, *MD* mean deviation.

Variables	Values
Eye, right:left	100:96
Age at first VF, mean \pm SD, y	47.7 \pm 12.1
Interval between first and 10th VFs, mean \pm SD, y	8.1 \pm 1.9
MD (first VF), mean \pm SD, dB	-16.4 \pm 8.0
MD (10th VF), mean \pm SD, dB	-20.8 \pm 8.6

Table 2. Demographic data of the patients for the validation. *VF* visual field, *SD* standard deviation, *MD* mean deviation.

The 68 test points in the HFA 10-2 test were clustered into 24 sectors (S1 mapping; Fig. 1A) using the Hierarchical Ordered Partitioning and Collapsing Hybrid (HOPACH)—Partitioning Around Medoids (PAM) algorithm²⁰ for the training data. VF mapping for glaucoma (29 sectors: S2 mapping; Fig. 1B) established with the same method in the former study¹⁶ were also used for comparison.

Figure 2 and Table 3 show the mean absolute error (MAE) values when predicting the total deviation (TD) values in the 10th VF. MAE values associated with sector-wise regression (S1 mapping) were significantly smaller than those with PLR, when the first three to first seven VFs were used ($P < 0.001$, linear mixed model adjusted for multiple comparisons using Benjamini and Hochberg's method²¹). MAE values with these two methods were not significantly different when the first eight VFs were used ($P > 0.05$). This value was significantly larger with the sector-wise regression (S1 mapping) than with PLR when the first nine VFs were used ($P = 0.0097$). MAE values with sector-wise regressions (S2 mapping) were significantly smaller than those with PLR when the first three to first six VFs were used ($P < 0.001$). This value was not significantly different when the first seven VFs were used ($P > 0.05$). In contrast, this value was significantly larger than that with PLR in other longer (first eight or nine) VF sequences ($P = 0.0059$ and $P < 0.001$ when the first eight and first nine VFs were used, respectively). MAE values with sector-wise regressions (S1 mappings) were significantly smaller than those with the S2 mapping when the first six to first nine VFs were used ($P = 0.021$ and $P < 0.001$ when the first six and the longer sequences were used, respectively). There was no significant difference otherwise. The MAE of mean sensitivity of total area (MS) was smaller than those with S1 only from 1st to 3rd to 1st to 4th VFs were used. In contrast, the prediction accuracy became far larger than any other methods when larger number of VFs were used.

Discussion

We developed a new clustering method for the HFA 10-2 test in RP. As a result, 68 test points were stratified into 24 clusters. The mapping obtained was considerably different from that in glaucoma (29 VF clusters), reflecting the difference in disease mechanisms. We also validated the usefulness of the cluster-wise regression based on mapping when predicting future VF. As a result, this approach enabled far more accurate prediction than PLR, in particular when the number of VF was small. The prediction accuracy was better than when the VF cluster for glaucoma was used.

Few studies have investigated the test–retest reproducibility of pointwise VF sensitivity in RP. However, such studies in glaucoma have shown that reproducibility is poor²² and as a result, PLR can be associated with a considerably high false-positive rate⁷. A possible approach to overcome this problem could be reducing the variability by dividing the VF into subsectors²³ and predicting progression based on this approach. Our study suggested that the MAE values associated with this new sector-wise regression model were significantly smaller than with PLR when between the first three and seven VFs were used. As described above, the prediction accuracies of cluster-wise regression and PLR are balanced between the variability of pointwise VF sensitivity and the masking effect of taking the average in sectors. Reflecting this point, PLR showed better prediction accuracy than the proposed cluster-wise regression when the first nine VFs were used, although no significant difference was observed between the proposed cluster-wise regression and PLR when the first eight VFs were used. On the other hand, the MAE of MS was smaller than those of sector-wise regression (both S1 and S2) when first to 3rd and first to 4th VFs were used, whereas the prediction accuracy became far larger than any other methods when larger number of VFs were used. We measured VF with an approximately 0.8-year interval. In other words, the cluster-wise regression was more useful than PLR for the duration of approximately 5 years (0.8×6 years).

To date, limited treatment options exist for RP. However, various attempts have been made. Vitamin A is such an example. However a recent meta-analysis suggested that treatment outcomes varied widely across studies^{24–31}.




Figure 1. Cluster mappings of the HFA 10-2 test (right eye). The 68 test points of the HFA 10-2 test were stratified into 24 sectors (A: S1). The sectors of S2 mapping (B: 29 clusters) was derived from previous study in glaucoma¹⁶. The left eye was mirror imaged.

A reason for contradicting results would be the different VF assessments across the studies³¹. The current results would be relevant when assessing the effect of such possible treatment using point-wise VF progression with HFA 10-2 test.

Kinetic perimetries, such as Goldmann perimetry, is another useful method to evaluate VF in the periphery in particular. However, quantitative assessment is not a primal/usual method or purpose with this type of perimetry. MD trend analysis also is used frequently, but it is not ideal to detect focal and early progression because the value reflects the total area. PLR may be a good solution, but it often is inaccurate particularly when a short VF series is used⁷⁻⁹, because measurement noise is considerable^{10,11}. Our results will be useful to assess the effects of any candidate treatment on the progression of VF with the HFA 10-2 test in a relatively short duration (such as up to 5 years). In addition, vision-related disability in daily life is associated closely with the results of HFA 10-2 testing in RP⁶. Therefore, our results also will be useful when predicting patient future disability.

S1 (RP) and S2 (glaucoma) clusters have similar cluster numbers (24 and 29). However, there are considerable differences in mappings. As we described previously¹⁶, S2 was mapped following the retinal nerve fiber layer (RNFL), reflecting the disease mechanism. For instance, Weber et al.³² reported a preserved “central isle” of the VF in advanced glaucoma patients and Hood et al.¹⁴ suggested that this is because the RNFLs in this area penetrate the optic disc margin at the temporal angle, which usually is less likely to be affected in cases of early-to-moderate glaucoma. As a result, test points in this region tended to be clustered in a sector (sectors 11, 16, and 17 in S2). This finding was not observed in S1; S1 was simply concentric, similarly to our prior findings³³. In addition, there was no cluster in S2 crossing the horizontal line, reflecting the distribution of RNFL. In contrast, most clusters near the horizontal line in S1 crossed the horizontal line (sectors 6, 9, 11, 12, 12, 14, 15, and 16), because the disease mechanism of RP is in retinal photoreceptors. This difference would have contributed to the better prediction accuracy of the cluster-wise regression based on S1 compared to that based on S2.

We previously compared the prediction performance of cluster-wise regression based on different VF mapping for glaucoma with large (fewer cluster numbers, 10) and small (fewer cluster numbers, 23) clusters. As described




Figure 2. Mean absolute error when predicting the 10th VF. MAE values associated with sector-wise regression (S1 mapping) were significantly smaller than those with PLR, when the first three to first seven VFs were used, and significantly smaller than those with the S2 mapping when the first six to first nine VFs were used. Data are expressed as mean ± SD.

	VF sequences	1-3	1-4	1-5	1-6	1-7	1-8	1-9
MAE (dB)	S1	12.9 ± 8.5	9.1 ± 6.2	6.9 ± 4.2	5.6 ± 3.1	4.6 ± 2.4	3.9 ± 1.9	3.4 ± 1.5
	S2	13.5 ± 8.6	9.4 ± 6.2	7.1 ± 4.1	5.9 ± 3	5.0 ± 2.3	4.2 ± 1.8	3.8 ± 1.5
	PLR	16.7 ± 9.9	11.2 ± 6.9	8.1 ± 4.6	6.4 ± 3.5	5.0 ± 2.7	4.0 ± 2.2	3.3 ± 1.7
	MS	9.4 ± 7.4	8.0 ± 5.4	7.2 ± 3.7	6.6 ± 2.9	6.3 ± 2.6	6.0 ± 2.5	6.0 ± 2.4
P values	S1 vs. PLR	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*	0.22	0.0097*
	S2 vs. PLR	<0.001*	<0.001*	<0.001*	<0.001*	0.38	0.0059*	<0.001*
	S1 vs. S2	0.16	0.29	0.22	0.025*	<0.001*	<0.001*	<0.001*
	S1 vs. MS	<0.001*	0.0011*	0.22	<0.001*	<0.001*	<0.001*	<0.001*
	S2 vs. MS	<0.001*	<0.001*	0.76	<0.001*	<0.001*	<0.001*	<0.001*
	PLR vs. MS	<0.001*	<0.001*	0.0011*	0.22	<0.001*	<0.001*	<0.001*

Table 3. Mean absolute error when predicting the 10th VF. * $P < 0.05$. VF visual field, MAE mean absolute error, PLR pointwise linear regression, MS mean sensitivity.

previously, the prediction accuracies of cluster-wise regression and PLR are balanced between the variability of pointwise VF sensitivity and the masking effect of taking the average in sectors. As a result, we showed that the prediction performance was better when small clusters were used in general. However this tendency was more obvious when small number of VFs were used¹⁷. In contrast, significantly smaller MAE values were observed with S1 compared to S2 when relatively longer VF series were used (from the first six to first nine VFs were used;

Fig. 2), despite the larger clusters in S1 than in S2. This implies that the reason for the better prediction accuracy with the proposed cluster-wise regression based on S1 compared to that based on S2 is not because of the cluster size, but because the nature of VF damage in RP is better reflected in S1.

In addition, it may be advantageous to change the schedule of the VF measurement. For instance, Crabb and Garway-Heath et al. have reported the usefulness of ‘wait-and-see’ approach in which VF measurements were intensively carried out at baseline and end of the observation period, rather than with a regular interval, resulted in an improved detection rate with fewer false-positives of progression³⁴. However, it has not been investigated whether this approach was also useful in the prediction of future VF as in the current study. Moreover, this approach is useful when monitoring VF progression in a fixed duration, such as in randomized control trials, however VF is usually followed up without deciding the ‘end date’ in clinics in the real world. Furthermore, according to a previous study investigating on VFs of glaucoma patients, it is useful to truncate sensitivities below 15–19 dB^{35,36}. However, we did not adopt this method, because it has not been used at clinical settings, such as in the Glaucoma Progression Analysis software (Carl Zeiss Meditec AG, Jena, Germany) or PROGRESSOR tool (Medisoft, London, UK).

One limitation of the study is that genetic information could not be considered. For instance, variants in many genes, including *P23H*³⁷, *PRPH2*³⁸, and *PROM1*^{39,40} genes, are associated with various phenotypes. It would be interesting to investigate the influence of genetics on VF mapping, which would be particularly important when identifying individuals who could benefit from retinal gene therapy⁴¹, even though there might be different progression rate within the same family. Second, we could not evaluate results with longer follow-up as in our previous study on glaucoma¹⁸, because of the shortage of such long VF series. This should be investigated in a future study. In the current study, clustering was performed using the HOPACH-PAM method²⁰, however different results may be obtained when different clustering method is applied, such as the k-means in conjunction with Dt contingency^{42,43}. Furthermore, peripheral (or full field) visual field with HFA 30-2 or 24-2 test results could not be collected in the study. Clustering in wider field area should be investigated in a future study.

In conclusion, a novel VF cluster was developed specifically for RP. A cluster-wise regression based on this mapping enabled accurate prediction of future VF.

Methods

This study was approved by the research ethics committee of the Graduate School of Medicine and Faculty of Medicine at the University of Tokyo and Kyoto University, and complied with the tenets of the Declaration of Helsinki. Written informed consent was given for patient information to be stored in the hospital database and used for research. Otherwise, based on the regulations of the Japanese Guidelines for Epidemiologic Study 2008, the study protocols did not require that each patient provide written informed consent. Instead, the protocol was posted at the outpatient clinic and/or website of the department to notify study participants.

Participants. This retrospective study included 858 eyes of 442 patients with RP obtained at the retinal clinic at Kyoto University Hospital. All patients underwent at least two reliable HFA 10-2 tests (SITA-standard program). The first examination was excluded from the study. An unreliable VF was defined as having $\geq 20\%$ fixation losses or $\geq 15\%$ false-positive errors, following manufacturer’s recommendations. After exclusion, eyes with ≥ 10 VF records (196 eyes/103 patients) were used as the testing dataset and the remaining 858 eyes (442 patients) were used as a training dataset. The training dataset was used to develop the VF cluster in RP. Only the initial VFs were used when a patient had ≥ 2 VFs. The testing dataset was used to validate the usefulness of the cluster-wise regression. Only the initial 10 VFs were included when a patient had > 10 VF test results.

Inclusion criteria were: (1) typical fundus findings of RP, such as bone spicule pigmentation, arteriolar attenuation, and waxy disc pallor; (2) reduction in a- and b-wave amplitudes or nondetectable full-field electroretinogram; (3) RP was the only disease causing VF damage; (4) no previous ocular surgery except for cataract extraction and intraocular lens implantation; (5) no other diseases of the anterior and posterior eye segments that could affect VF, including cataracts, except for clinically insignificant senile cataracts; and (6) age at least 20 years. Those with intraocular surgery, including cataract surgery, during the observation period were excluded.

VF sectors. The 68 test points in the HFA 10-2 test were clustered using HOPACH-PAM algorithm²⁰. The details of this method have been reported previously¹⁶. In brief, the method is a hybrid between hierarchical ordered partitioning and collapsing, whereby a hierarchical tree is built by recursively partitioning a data set, while ordering and possibly collapsing clusters at each level. HOPACH builds a hierarchical tree of clusters by recursively partitioning the data, while ordering and possibly collapsing clusters at each level to identify finite structures in a dataset using the Mean Median Split Silhouette criteria^{20,44}. A strength of this approach is that the optimum number of clusters is inferred automatically²⁰, unlike many other clustering methods, such as k-means and hierarchical clustering methods, where the number of optimum clusters is decided using additional statistical analyses to determine their separability.

Statistical analysis. Following creation of the VF cluster (S1 mapping; Fig. 1A), mean absolute error (MAE) of the cluster-wise regression was evaluated using the testing dataset, as follows: (1) 68 test points were stratified into 24 sectors for each of the initial three VFs. (2) In each sector, mean TD values were calculated and allocated to all test points belonging to the sector. (3) The 68 TD values of the 10th VF were predicted by extrapolating the allocated TD value against time at each test point. These predictions of 10th VFs were iterated using other VF sequences (from first-fourth to first-ninth VFs). For comparison, similar calculations were conducted using the PLR, MS and also another sector-wise regression basing on a VF mapping for glaucoma (29 sectors: S2 mapping; Fig. 1B)¹⁶. These MAE values were compared among the methods using the linear mixed

model, in which the subject was the random effect^{45,46}. Benjamini and Hochberg's method was used to adjust for multiple comparisons²¹.

All analyses were conducted using R software version 3.5.2. (the R Foundation for Statistical Computing, Vienna, Austria).

Received: 5 January 2021; Accepted: 31 March 2021

Published online: 06 May 2021

References

- Hartong, D. T., Berson, E. L. & Dryja, T. P. Retinitis pigmentosa. *Lancet* **368**, 1795–1809. [https://doi.org/10.1016/s0140-6736\(06\)69740-7](https://doi.org/10.1016/s0140-6736(06)69740-7) (2006).
- Swanson, W. H., Feliu, J. & Birch, D. G. Effect of stimulus size on static visual fields in patients with retinitis pigmentosa. *Ophthalmology* **107**, 1950–1954. [https://doi.org/10.1016/s0161-6420\(00\)00356-0](https://doi.org/10.1016/s0161-6420(00)00356-0) (2000).
- Inoue, T. *et al.* A prediction method of visual field sensitivity using fundus autofluorescence images in patients with retinitis pigmentosa. *Invest Ophthalmol. Vis. Sci.* **61**, 51. <https://doi.org/10.1167/iovs.61.10.51> (2020).
- Fujiwara, K. *et al.* Assessment of central visual function in patients with retinitis pigmentosa. *Sci. Rep.* **8**, 8070. <https://doi.org/10.1038/s41598-018-26231-9> (2018).
- Iijima, H. Visual loss and perimetric sensitivity in eyes with retinitis pigmentosa. *Jpn. J. Ophthalmol.* **57**, 563–567. <https://doi.org/10.1007/s10384-013-0271-7> (2013).
- Sumi, I., Matsumoto, S., Okajima, O. & Shirato, S. The relationship between visual disability and visual scores in patients with retinitis pigmentosa. *Jpn. J. Ophthalmol.* **44**, 82–87. [https://doi.org/10.1016/s0021-5155\(99\)00171-9](https://doi.org/10.1016/s0021-5155(99)00171-9) (2000).
- De Moraes, C. G., Liebmann, C. A., Susanna, R. Jr., Ritch, R. & Liebmann, J. M. Examination of the performance of different pointwise linear regression progression criteria to detect glaucomatous visual field change. *Clin. Exp. Ophthalmol.* **40**, e190–196. <https://doi.org/10.1111/j.1442-9071.2011.02680.x> (2012).
- Taketani, Y., Murata, H., Fujino, Y., Mayama, C. & Asaoka, R. How many visual fields are required to precisely predict future test results in glaucoma patients when using different trend analyses?. *Invest Ophthalmol. Vis. Sci.* **56**, 4076–4082. <https://doi.org/10.1167/iovs.14-16341> (2015).
- Nouri-Mahdavi, K., Hoffman, D., Gaasterland, D. & Caprioli, J. Prediction of visual field progression in glaucoma. *Invest Ophthalmol. Vis. Sci.* **45**, 4346–4351. <https://doi.org/10.1167/iovs.04-0204> (2004).
- Bengtsson, B. & Heijl, A. False-negative responses in glaucoma perimetry: Indicators of patient performance or test reliability?. *Invest. Ophthalmol. Vis. Sci.* **41**, 2201–2204 (2000).
- Henson, D. B., Evans, J., Chauhan, B. C. & Lane, C. Influence of fixation accuracy on threshold variability in patients with open angle glaucoma. *Invest Ophthalmol. Vis. Sci.* **37**, 444–450 (1996).
- Flammer, J., Drance, S. M., Fankhauser, F. & Augustiny, L. Differential light threshold in automated static perimetry. Factors influencing short-term fluctuation. *Arch Ophthalmol.* **102**, 876–879 (1984).
- Flammer, J., Drance, S. M. & Zulauf, M. Differential light threshold. Short- and long-term fluctuation in patients with glaucoma, normal controls, and patients with suspected glaucoma. *Arch. Ophthalmol.* **102**, 704–706 (1984).
- Hood, D. C., Raza, A. S., de Moraes, C. G., Liebmann, J. M. & Ritch, R. Glaucomatous damage of the macula. *Prog. Retin. Eye Res.* **32**, 1–21. <https://doi.org/10.1016/j.preteyeres.2012.08.003> (2013).
- de Moraes, C. G. *et al.* Defining 10-2 visual field progression criteria: exploratory and confirmatory factor analysis using pointwise linear regression. *Ophthalmology* **121**, 741–749. <https://doi.org/10.1016/j.ophtha.2013.10.018> (2014).
- Asaoka, R. Mapping glaucoma patients' 30-2 and 10-2 visual fields reveals clusters of test points damaged in the 10-2 grid that are not sampled in the sparse 30-2 grid. *PLoS ONE* **9**, e98525. <https://doi.org/10.1371/journal.pone.0098525> (2014).
- Hirasawa, K., Murata, H., Hirasawa, H., Mayama, C. & Asaoka, R. Clustering visual field test points based on rates of progression to improve the prediction of future damage. *Invest Ophthalmol. Vis. Sci.* **55**, 7681–7685. <https://doi.org/10.1167/iovs.14-15040> (2014).
- Hirasawa, K., Murata, H. & Asaoka, R. Revalidating the usefulness of a “sector-wise regression” approach to predict glaucomatous visual function progression. *Invest Ophthalmol. Vis. Sci.* **56**, 4332–4335. <https://doi.org/10.1167/iovs.15-16694> (2015).
- Aoki, S. *et al.* Investigating the usefulness of a cluster-based trend analysis to detect visual field progression in patients with open-angle glaucoma. *Br. J. Ophthalmol.* **101**, 1658–1665. <https://doi.org/10.1136/bjophthalmol-2016-310069> (2017).
- van der Laan, M. & Pollard, K. S. A new algorithm for hybrid hierarchical clustering with visualization and the bootstrap. *J. Stat. Plan. Inf.* **117**, 275–303. [https://doi.org/10.1016/s0378-3758\(02\)00388-9](https://doi.org/10.1016/s0378-3758(02)00388-9) (2003).
- Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J. R. Stat. Soc. Ser. B (Methodological)* **57**, 289–300 (1995).
- Artes, P. H., Iwase, A., Ohno, Y., Kitazawa, Y. & Chauhan, B. C. Properties of perimetric threshold estimates from full threshold, SITA standard, and SITA fast strategies. *Invest. Ophthalmol. Vis. Sci.* **43**, 2654–2659 (2002).
- Suzuki, Y. *et al.* Mathematical and optimal clustering of test points of the central 30-degree visual field of glaucoma. *J. Glaucoma* **10**, 121–128 (2001).
- Berson, E. L. *et al.* A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. *Arch. Ophthalmol.* **111**, 761–772. <https://doi.org/10.1001/archophth.1993.01090060049022> (1993).
- Berson, E. L. *et al.* Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: Subgroup analyses. *Arch. Ophthalmol.* **122**, 1306–1314. <https://doi.org/10.1001/archophth.122.9.1306> (2004).
- Berson, E. L. *et al.* Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. *Arch. Ophthalmol.* **122**, 1297–1305. <https://doi.org/10.1001/archophth.122.9.1297> (2004).
- Hoffman, D. R. *et al.* A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. *Am. J. Ophthalmol.* **137**, 704–718. <https://doi.org/10.1016/j.ajo.2003.10.045> (2004).
- Hoffman, D. R. *et al.* Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): A randomized clinical trial. *JAMA Ophthalmol.* **132**, 866–873. <https://doi.org/10.1001/jamaophthol.2014.1634> (2014).
- Hughbanks-Wheaton, D. K. *et al.* Safety assessment of docosahexaenoic acid in X-linked retinitis pigmentosa: The 4-year DHAX trial. *Invest Ophthalmol. Vis. Sci.* **55**, 4958–4966. <https://doi.org/10.1167/iovs.14-14437> (2014).
- Hoffman, D. R. *et al.* Docosahexaenoic acid slows visual field progression in X-linked retinitis pigmentosa: Ancillary outcomes of the DHAX Trial. *Invest Ophthalmol. Vis. Sci.* **56**, 6646–6653. <https://doi.org/10.1167/iovs.15-17786> (2015).
- Schwartz, S. G., Wang, X., Chavis, P., Kuriyan, A. E. & Abariga, S. A. Vitamin A and fish oils for preventing the progression of retinitis pigmentosa. *Cochrane Database Syst. Rev.* **6**, 8428. <https://doi.org/10.1002/14651858.CD008428.pub3> (2020).
- Weber, J., Schultze, T. & Ulrich, H. The visual field in advanced glaucoma. *Int. Ophthalmol.* **13**, 47–50 (1989).
- Ogino, K. *et al.* Concentric division of 10 degrees visual field tests in retinitis pigmentosa. *Jpn. J. Ophthalmol.* **57**, 268–274. <https://doi.org/10.1007/s10384-013-0235-y> (2013).
- Crabb, D. P. & Garway-Heath, D. F. Intervals between visual field tests when monitoring the glaucomatous patient: wait-and-see approach. *Invest Ophthalmol. Vis. Sci.* **53**, 2770–2776. <https://doi.org/10.1167/iovs.12-9476> (2012).

35. Gardiner, S. K., Swanson, W. H. & Demirel, S. The effect of limiting the range of perimetric sensitivities on pointwise assessment of visual field progression in glaucoma. *Invest Ophthalmol. Vis. Sci.* **57**, 288–294. <https://doi.org/10.1167/iovs.15-18000> (2016).
36. Pathak, M., Demirel, S. & Gardiner, S. K. Reducing variability of perimetric global indices from eyes with progressive glaucoma by censoring unreliable sensitivity data. *Transl. Vis. Sci. Technol.* **6**, 11. <https://doi.org/10.1167/tvst.6.4.11> (2017).
37. Dryja, T. P. *et al.* Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. *N. Engl. J. Med.* **323**, 1302–1307. <https://doi.org/10.1056/NEJM199011083231903> (1990).
38. Boon, C. J. *et al.* The spectrum of retinal dystrophies caused by mutations in the peripherin/RDS gene. *Prog. Retin. Eye Res.* **27**, 213–235. <https://doi.org/10.1016/j.preteyeres.2008.01.002> (2008).
39. Fujinami, K. *et al.* Clinical and genetic characteristics of 10 Japanese patients with PROM1-associated retinal disorder: A report of the phenotype spectrum and a literature review in the Japanese population. *Am. J. Med. Genet. C Semin. Med. Genet.* <https://doi.org/10.1002/ajmg.c.31826> (2020).
40. Cehajic-Kapetanovic, J. *et al.* Clinical and molecular characterization of PROM1-related retinal degeneration. *JAMA Netw. Open* **2**, e195752. <https://doi.org/10.1001/jamanetworkopen.2019.5752> (2019).
41. Russell, S. *et al.* Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial. *Lancet* **390**, 849–860. [https://doi.org/10.1016/S0140-6736\(17\)31868-8](https://doi.org/10.1016/S0140-6736(17)31868-8) (2017).
42. Phu, J. *et al.* Pattern recognition analysis reveals unique contrast sensitivity isocontours using static perimetry thresholds across the visual field. *Invest Ophthalmol. Vis. Sci.* **58**, 4863–4876. <https://doi.org/10.1167/iovs.17-22371> (2017).
43. Swain, P. H. & King, R. C. Two effective feature selection criteria for multispectral remote sensing. *LARS Technical Reports* **39** (1973).
44. Pollard KS, Van der Laan MJ & Wall G. *hopach: Hierarchical Ordered Partitioning and Collapsing Hybrid (HOPACH) 2012. [R package insert] version 2.10.0, <http://www.bioconductor.org>* (2012).
45. Baayen, R. H., Davidson, D. J. & Bates, D. M. Mixed-effects modeling with crossed random effects for subjects and items. *J. Mem. Lang.* **59**, 390–412. <https://doi.org/10.1016/j.jml.2007.12.005> (2008).
46. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. *J. Stat. Softw.* <https://doi.org/10.18637/jss.v067.i01> (2015).

Author contributions

T.O. and R.A. contributed for the design of the work, the data analysis and drafting the manuscript. A.O. and M.M. contributed for the data acquisition and supervision of the study. Y.F., H.M., K.A., R.O. and T.I. contributed for the supervision of the study. All authors contributed to the final approval of the version published.

Funding

This study was supported in part by Grants (19H01114, 18KK0253, and 20K09784 (RA)) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Translational Research program; grants from the Strategic Promotion for practical application of Innovative medical Technology (TR-SPRINT) from Japan Agency for Medical Research and Development (AMED); Grants AIP acceleration research from the Japan Science and Technology Agency (RA); a grant from the Japanese Retinitis Pigmentosa Society (JRPS) (RA).

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to R.A.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021